RT Journal Article
T1 Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
A1 Ferrín, Gustavo
A1 Guerrero, Marta
A1 Amado, Víctor
A1 Rodríguez-Perálvarez, Manuel
A1 De la Mata, Manuel
K1 mTOR
K1 Everolimus
K1 Sirolimus
K1 Hepatocellular carcinoma
K1 Liver transplantation
K1 Sorafenib
K1 Serina-treonina quinasas TOR
K1 Carcinoma hepatocelular
K1 Trasplante de hígado
AB Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and occurs mainly in patients with liver cirrhosis. The mammalian target of rapamycin (mTOR) signaling pathway is involved in many hallmarks of cancer including cell growth, metabolism re-programming, proliferation and inhibition of apoptosis. The mTOR pathway is upregulated in HCC tissue samples as compared with the surrounding liver cirrhotic tissue. In addition, the activation of mTOR is more intense in the tumor edge, thus reinforcing its role in HCC proliferation and spreading. The inhibition of the mTOR pathway by currently available pharmacological compounds (i.e., sirolimus or everolimus) is able to hamper tumor progression both in vitro and in animal models. The use of mTOR inhibitors alone or in combination with other therapies is a very attractive approach, which has been extensively investigated in humans. However, results are contradictory and there is no solid evidence suggesting a true benefit in clinical practice. As a result, neither sirolimus nor everolimus are currently approved to treat HCC or to prevent tumor recurrence after curative surgery. In the present comprehensive review, we analyzed the most recent scientific evidence while providing some insights to understand the gap between experimental and clinical studies.
PB MDPI
YR 2020
FD 2020-02-13
LK http://hdl.handle.net/10668/3716
UL http://hdl.handle.net/10668/3716
LA en
NO Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci. 2020 Feb 13;21(4):1266
DS RISalud
RD Apr 10, 2025